<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925041</url>
  </required_header>
  <id_info>
    <org_study_id>Avedro T1</org_study_id>
    <nct_id>NCT00925041</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Vedera KXS for the Treatment of Spherical Myopia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical investigation is to evaluate the safety and efficacy of the&#xD;
      Vedera KXS in sighted eyes for the correction of spherical myopia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UCVA 20/40 or better</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Kxl Vedera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vedera KXS</intervention_name>
    <description>one treatment with the Vedera KXS</description>
    <arm_group_label>Kxl Vedera</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be undergoing surgery for the correction of myopia&#xD;
&#xD;
          -  Intended treatment from -0.5 to -6.0 D of spherical myopia&#xD;
&#xD;
          -  Must have 0.50 D or less astigmatic component.&#xD;
&#xD;
          -  Must have bilateral physiologic myopia&#xD;
&#xD;
          -  BSCVA of 20/25 or better in each eye&#xD;
&#xD;
          -  Must have had a stable refraction (0.5 D or less change in spheroequivalent) for at&#xD;
             least one year, objectively documented (by previous clinical records, eyeglass&#xD;
             prescriptions, etc. over one year old)&#xD;
&#xD;
          -  Patients who are contact lens wearers must have hard or gas permeable lenses&#xD;
             discontinued for two weeks and soft lenses discontinued for three days prior to the&#xD;
             preoperative evaluation&#xD;
&#xD;
          -  Must be at least 18 years of age&#xD;
&#xD;
          -  Corneal topography must be normal, as judged by the investigator&#xD;
&#xD;
          -  Must have a minimal corneal thickness of 475 microns&#xD;
&#xD;
          -  Must sign a written Informed Consent form acknowledging their awareness of their&#xD;
             participation in this study, the alternative treatments available, the risks involved,&#xD;
             and the investigative nature of the procedure, and other issues which conform to the&#xD;
             standard of care for Informed Consent practices&#xD;
&#xD;
          -  Must be willing and capable of returning for scheduled follow-up examinations for 24&#xD;
             months after treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unable or unwilling to sign the informed consent form.&#xD;
&#xD;
          -  Anterior segment pathology&#xD;
&#xD;
          -  Residual, recurrent or active ocular disease&#xD;
&#xD;
          -  Patients who have undergone previous intraocular or corneal surgery involving the&#xD;
             stroma in the eye to be operated.&#xD;
&#xD;
          -  History of herpes keratitis&#xD;
&#xD;
          -  Patients with diagnosed autoimmune disease, systemic connective tissue diseases or&#xD;
             atopic syndrome, diabetes mellitus, or taking systemic medications (i.e.,&#xD;
             corticosteroids or antimetabolites) likely to affect wound healing.&#xD;
&#xD;
          -  Irregular central keratometry/topography readings with irregular topography patterns&#xD;
             or keratometry mires, including signs of keratoconus.&#xD;
&#xD;
          -  Patients with known sensitivity to study medications.&#xD;
&#xD;
          -  Intraocular pressure of &gt; 23 mm Hg by Goldmann applanation tonometry, a history of&#xD;
             glaucoma, or glaucoma suspect.&#xD;
&#xD;
          -  Women who are pregnant or nursing or who plan to become pregnant over the course of&#xD;
             their participation in this investigation.&#xD;
&#xD;
          -  Participation in other ophthalmic clinical trials during this clinical investigation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beyoglu Eye Research and Education Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 18, 2009</study_first_submitted>
  <study_first_submitted_qc>June 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2009</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

